SAB Biotherapeutics
SABS • NASDAQ
SAB Biotherapeutics is a biotechnology company in the healthcare sector trading on NASDAQ, led by CEO Samuel J. Reich, with a market cap of $269.2M.
Market Cap$269.2M
Employees57.0
CEOSamuel J. Reich
CountryUnited States of America
Healthcare
Biotechnology
Next EarningsMay 8, 2026 · In 3 weeksQ1 2026
Financials
SAB Biotherapeutics FAQ
Common questions about SAB Biotherapeutics
SAB Biotherapeutics is scheduled to report earnings for Q1 2026 on May 8, 2026.
SAB Biotherapeutics has approximately 57 employees.